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Abstract
Invasive fungal infections, particularly those caused by
Candida species, are not uncommon in critically ill
patients and are associated with considerable
morbidity and mortality. Diagnosis and management
of these infections can be challenging. In this review,
we will briefly discuss recent epidemiological data on
invasive candidiasis and current diagnostic approaches
before concentrating on antifungal treatments.
Background
Invasive fungal infections in critically ill patients are as-
sociated with considerable morbidity and mortality.
Candida and Aspergillus species are the most frequent
causes of healthcare-associated fungal infections in these
patients [1]. Although Candida infections are the most
frequent fungal infections in ICU patients, invasive asper-
gillosis is associated with higher morbidity and mortality
rates, even in the absence of traditional hematological risk
factors [2]. Occasionally, cryptococcosis, pneumocystosis,
or zygomycosis may also be encountered in the ICU
setting in patients with solid organ or hematopoietic
stem cell transplantation, acquired immunodeficiency
syndrome, cancer, or hematological malignancies. Because
Candida species account for 70–90 % of invasive fungal
infections, this overview will focus on invasive candidiasis
and the important aspects that must be considered as part
of optimizing treatment.
Epidemiology
In the USA, Candida species are responsible for 8–10 %
of bloodstream infections (BSI) and are the fourth most
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common bloodstream pathogen. In Europe, Candida
species only account for 2–3 % of BSI and are ranked as
the 6th–10th most frequent pathogen [3]. Approximately
30–35 % of all episodes of candidemia occur in ICU
patients [4]. In the Extended Prevalence of Infection in
Intensive Care (EPIC II) point prevalence study [5],
Candida was isolated in 17 % of infected culture-positive
patients. Several studies have reported increasing inci-
dence rates of candidemia in ICUs over recent years
[6, 7], although population-based studies have suggested
reduced incidence rates possibly related to improved
infection control practices in high-risk patients [8, 9].
Invasive candidiasis is a highly lethal infection associated
with mortality rates between 40 and 60 % [6, 7, 10, 11].
The five most common Candida species are Candida
albicans, Candida glabrata, Candida tropicalis, Candida
parapsilosis, and Candida krusei [12]. C. albicans was pre-
viously the predominant species isolated in patients with
invasive candidiasis, accounting for 65–70 % of the total
number of Candida isolates. However, the epidemiology
has changed in recent years, with non-albicans species
now responsible for about half of the cases in some cen-
ters [10, 13, 14]. C. parapsilosis tends to be more frequent
in southern Europe, Australia, and Latin America than
elsewhere [10, 15–17], and C. glabrata is more frequent in
the older population than in middle-aged adults [7, 15].
Non-albicans species often have reduced susceptibilities
or even intrinsic resistance to azoles or echinocandins
[17]. These epidemiological trends underscore the need to
perform large longitudinal studies to obtain data that can
be used to guide empirical antifungal therapy.
Diagnosis
Prompt and accurate diagnosis of invasive fungal infection
is crucial so that appropriate antifungal agents can be
started rapidly. However, early diagnosis is not always
easy. Microscopic examination is rapid and can be helpful
but a negative result does not exclude infection [18, 19].
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Blood cultures are positive in only 50–70 % of cases of
Candida BSI [20]. Furthermore, it can take several days
before Candida is identified at the species level and anti-
fungal susceptibility data are available. Moreover, blood
cultures are rarely positive in patients with deep-seated
candidiasis [20]. In such patients, cultures of infected
tissues can be performed but have their own limitations,
including the need for invasive surgical procedures and
poor sensitivity [20].
Recently, nonculture-based diagnostic tests have been
developed for detection in blood of components of the
fungal cell wall (such as mannan and β-D-glucan (BDG))
by immunoassays, of DNA by PCR, and of antibodies by
serology. The performance of BDG assays in invasive
fungal infections has been assessed in three systematic
reviews. In the subgroup of patients with proven infec-
tion, the pooled sensitivities and specificities of BDG
were 79.1, 87.7, and 78 %, respectively [21–23]. Import-
antly, BDG assays are not species specific so further tests
are needed to identify the specific fungus. In patients
with suspected invasive candidiasis, the presence of ele-
vated circulating levels of Candida mannan antigen in
the blood had a sensitivity of 58 % and a specificity of
93 % [24]. In the same group of patients, the detection
of anti-mannan antibodies had a sensitivity of 59 % and
a specificity of 83 %. The sensitivity increased to 83 %
when the mannan and anti-mannan assays were com-
bined, but the specificity remained similar at 86 %. PCRs
for fungi continue to be challenging for technical rea-
sons and there are no commercially available tests at
present. In a review of more than 50 standard, nested, or
real-time PCRs [25], the pooled sensitivity and specificity
were 95 and 92 %, respectively, for invasive candidiasis.
Combining several markers may prove more useful. A
technology combining PCR and nanoparticle-based
hybridization, the T2 magnetic resonance-based bio-
sensing technology platform, can detect as little as 1 col-
ony-forming unit/ml of the five most common
Candida species [26] and was shown to have an overall
specificity of 99.4 % for invasive candidemia [27]. This test
is expensive to perform, however, and although costs may
be balanced by more accurate earlier diagnosis with re-
duced administration of antifungal agents and reduced
mortality rates [28], further studies are needed to validate
its use and assess its cost–benefit ratio.
Risk factors
Numerous risk factors for invasive Candida infections
have been identified, including higher Acute Physiology
and Chronic Health Evaluation II scores, diabetes mellitus,
renal insufficiency, surgery (especially abdominal surgery),
pancreatitis, the use of broad-spectrum antibiotics, paren-
teral nutrition, hemodialysis, mechanical ventilation, the
presence of central vascular catheters, and therapy with
immunosuppressive agents [29–34]. The development of
invasive Candida infections is often preceded by extensive
colonization of the skin or of the mucus membranes of
the gastrointestinal and urogenital tracts, and the degree
of colonization, assessed using the Colonization Index,
has been shown to be an independent risk factor for de-
velopment of candidiasis [35, 36].
Several prediction rules and scores based on clinical,
laboratory, and microbiological parameters have been pro-
posed to help clinicians identify patients at high risk of de-
veloping invasive fungal infections [32, 33, 35, 37–41].
Ostrosky-Zeichner et al. [40] proposed a prediction rule
characterized by a very high negative predictive value
(0.97) and including the following parameters: use of sys-
temic antibiotic therapy, total parenteral nutrition, dialysis,
steroids or immunosuppressive agents, major surgery or
pancreatitis, and the presence of a central venous catheter.
The Candida score, an easy-to-use assessment system pro-
posed by Leon et al. [32, 33], integrates four risk factors
(total parenteral nutrition, surgery, multifocal Candida
colonization, and severe sepsis) and also has a high nega-
tive predictive value (0.98) to rule out invasive candidiasis
[33]. However, colonization surveillance cultures are ex-
pensive and their precise value remains unclear [42].
More recently, biomarkers of fungal infection have
been suggested to assist in decisions to start or stop an-
tifungals. BDG was superior to the Colonization Index
or the Candida score for the prediction of intraabdominal
candidiasis in high-risk surgical and ICU patients, with a
cutoff value of 80 pg/ml [43]. Similarly a prospective
observational study demonstrated that BDG was more
accurate than the Candida score and the Colonization
Index for early prediction of invasive Candida infection in
patients at risk for Candida sepsis [44], with 250 pg/ml
identified as the best cutoff value [44]. A decrease in BDG
levels during antifungal treatment for invasive candidiasis
correlated with a successful clinical response with a posi-
tive predictive value of 90 % [45]. However, despite its
promising performance for excluding invasive infection
and orienting the duration of therapy, the cost of the
BDG test and a lack of large validation studies currently
limit its use.
Management
Antifungal treatment can be considered as prophylactic
(in patients at high risk of fungal infection), empiric
(triggered by clinical signs of fungal infection, e.g.,
persistent fever in the presence of risk factors), preemptive
(triggered by microbiological or biomarker evidence of
fungus without actual infection), and definitive (after posi-
tive microbiological confirmation of strain and sensitivity
of fungus).
Prophylactic antifungal agents are recommended in
just a few specific situations and most treatments are
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given on an empiric basis [46]. Although use of preemp-
tive therapy is gaining interest, more studies are needed
to better define which patients may benefit from this ap-
proach [47] and whether more widespread use of anti-
fungal agents may negatively influence fungal ecology
[48]. In a recent study of 241 ICU patients requiring
emergency gastrointestinal surgery for intraabdominal
infection, preemptive therapy with micafungin was not
effective at reducing the development of invasive candid-
iasis compared with placebo, although there was some
suggestion that this may have been the result of the pre-
emptive therapy being administered too late [49].
There are three main groups of antifungals: the azoles,
the polyenes, and the echinocandins. The selection of an
antifungal regimen is based on multiple factors, includ-
ing epidemiological data, patient characteristics, hospital
setting, fungal strain, site of infection, and safety profiles
of the antifungal agents. Although different antifungals
can show comparable efficacy in treating candidemia,
their differences in terms of pharmacokinetics (PK) and
pharmacodynamics (PD) (including fungistatic versus
fungicidal activity, need for dose adjustment in case of
hepatic or renal failure and drug–drug interactions),
toxicity, and selection pressure remain significant and
can affect the clinical outcome of fragile patient popula-
tions, such as the critically ill. Specific guidelines are
therefore available to help direct optimal antifungal
choices [12, 46, 50]. The European Society of Clinical
Microbiology and Infectious Diseases (ESCMID) guide-
lines no longer consider fluconazole the drug of choice for
invasive candidiasis, and endorse the use of echinocandins
as first-line empiric treatment [46]. The rationale for this
statement is that, compared with fluconazole, echino-
candins show a broader spectrum of activity, fungicidal
activity, an excellent safety profile, and fewer drug–drug
interactions. The recent Infectious Diseases Society of
America (IDSA) guidelines also recommend echinocan-
dins for initial therapy [12]. All three available echino-
candins (caspofungin, micafungin, and anidulafungin)
penetrate well into the biofilm formed on vascular de-
vices. Nevertheless, fluconazole remains a well-known
and well-tolerated antifungal with a significantly lower
cost compared with the echinocandins and may still
be of value in clinically stable patients who have had
no recent azole exposure or have known fluconazole-
sensitive organisms [12].
Dosing of antifungal agents
Pathophysiological changes associated with critical illness
can change drug concentrations so that they are signifi-
cantly different from those observed in noncritically ill pa-
tients. In these circumstances, if standard dosing is used,
then suboptimal concentrations (either too low or un-
necessarily high) may result, putting the patient at risk of
clinical failure or drug toxicity. Antifungal agents tend not
to be as markedly affected by altered PK in critical illness.
The drugs are mostly lipophilic, hepatically metabolized,
and with high protein binding. Drugs such as fluconazole
are an exception to these characteristics. Use of renal re-
placement therapy (RRT) can influence the clearance of
some antifungal drugs, particularly those that are predom-
inantly eliminated by renal mechanisms, are not highly
protein bound, and have low molecular weights, notably
the azoles and 5-flucytosine. Moreover, different RRT
characteristics, including the specific mode, membrane
characteristics, flow rates, and duration of treatment, may
influence the effects of RRT on drug PK [51] and should
be taken into consideration when evaluating dosing.
From a PD perspective, efficacy for the triazole anti-
fungals is described in terms of the ratio of the area
under the concentration–time curve (AUC) to the mini-
mum inhibitory concentration (MIC). The echinocan-
dins are mostly described in terms of the ratio of the
maximum concentration in a dosing interval (Cmax) to
the MIC. Fluconazole is the antifungal for which most of
the dosing challenges for critically ill patients exist. Data
comparing the PK of fluconazole in critically ill patients
and noncritically ill patients show a lower AUC, includ-
ing both Cmax and minimum concentration during a
dosing interval [52]. Lack of achievement of the AUC/
MIC target in particular is associated with doses <6 mg/
kg, suggesting that standard maintenance dosing should
be at this level. In sepsis, interstitial fluid concentrations
of fluconazole in tissues, which are commonly the target
site of infection, are lower than those in plasma by
~50 % [53]. These data suggest that reduced efficacy
may occur in states of microvascular failure. In the pres-
ence of RRT, very high drug clearances of fluconazole
are common, necessitating even higher doses than in pa-
tients with normal renal function. Few data are available
regarding altered PK of posaconazole, itraconazole, or
isavuconazole in critically ill patients. For voriconazole,
the unpredictability of dosing for individual patients
tends to mean that critical illness does not in itself result
in differences to dosing recommendations—although is-
sues such as drug–drug interactions may be more com-
mon in these patients, necessitating more careful dose
considerations.
There are only sparse data to suggest that the PK of
echinocandins changes significantly in critically ill pa-
tients and they are not greatly influenced by RRT. A re-
duced AUC has been described for anidulafungin and
caspofungin with a lower Cmax [52], but this is yet to be
correlated with reduced efficacy. Use of adequate loading
doses is particularly important for these agents (except
micafungin), with caspofungin not even reaching steady-
state concentrations by day 3 of treatment [54]. The high
protein binding of echinocandins may mean that the
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presence of hypoalbuminemia could severely alter the
PK. Preliminary data for micafungin demonstrate an
altered volume of distribution with changes in serum
albumin concentrations [55]. There are again few data
for the various amphotericin formulations or flucytosine.
Table 1 presents a summary guidance based on current
understanding of how doses should be adjusted in differ-
ent subpopulations of critically ill patients. Therapeutic
drug monitoring (TDM) is likely to play an increasingly
important role in our antifungal dosing decisions, and
recommendations for when TDM should be used with
the different agents available have been published re-
cently [56]. To the best of our knowledge, there are no
studies in critically ill patients with invasive fungal infec-
tions that have measured the patient outcome benefits
of a dose-optimization approach, such as TDM. Until
such data become available, results from other patient
populations, which support achievement of PK/PD tar-
gets and the use of TDM, suggest that we should actively
optimize antifungal dosing, including the use of TDM
where available [57–60].
Conclusion
Fungal infections are associated with considerable mor-
bidity and mortality in ICU patients. Therapies are often
started late because these infections can be difficult to
diagnose. Until rapid susceptibility testing is available,
empiric therapy should be used based on known patient
characteristics, including risk factors, local fungal micro-
biology patterns, hospital setting, and site of infection.
Further data from epidemiological studies are needed to
help better define high-risk populations, and thus guide
empirical antifungal choices. Further development of
PCR and other diagnostic and predictive tests will prob-
ably lead to increased use of preemptive therapy, but
studies are needed to confirm the beneficial effects of
preemptive therapy on outcomes before this approach
can be recommended. Dosing needs are different in ICU
compared to non-ICU patients but data remain limited,
with current evidence suggesting that dosing should be
individualized according to patient characteristics in
order to ensure optimal outcomes.
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